Monday, December 11, 2023

First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial.

from Latest Science News -- ScienceDaily https://ift.tt/qTKcfMN
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Only 13 % know: The one-minute self-exam that could save young men’s lives

A new survey shows most Americans wrongly think testicular cancer is an older man's issue, despite it most commonly affecting men aged 2...